The estimated Net Worth of Sarah Kathryn Rouan is at least $25 dollars as of 8 February 2024. Sarah Rouan owns over 25,000 units of Navidea Biopharmaceuticals Inc stock worth over $25 and over the last 6 years Sarah sold NAVB stock worth over $0.
Sarah has made over 3 trades of the Navidea Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Sarah exercised 25,000 units of NAVB stock worth $208,000 on 8 February 2024.
The largest trade Sarah's ever made was exercising 30,000 units of Navidea Biopharmaceuticals Inc stock on 19 January 2024 worth over $249,600. On average, Sarah trades about 4,168 units every 123 days since 2019. As of 8 February 2024 Sarah still owns at least 25,000 units of Navidea Biopharmaceuticals Inc stock.
You can see the complete history of Sarah Rouan stock trades at the bottom of the page.
Sarah's mailing address filed with the SEC is C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121.
Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen, eLife Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: